LaharaBio develops non-invasive therapeutics utilizing low-intensity vibration (LIV) to modulate immunity through mechanical signals. This platform harnesses mechanobiology to restore and enhance immune function by engaging cellular structures like the cytoskeleton and nucleus. The technology aims to provide a drug-free method to improve immune cell activation, proliferation, and resilience, particularly in contexts like aging and cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional immunotherapies often involve complex drug regimens or invasive procedures, leading to significant side effects and limited patient adherence. Immune exhaustion and age-related immune decline also present challenges in effectively treating diseases like cancer and in maintaining overall immune health.
Solution
Lahara Bio is developing a novel therapeutic platform that utilizes low-intensity vibration (LIV) to modulate immune function non-invasively. This approach leverages principles of mechanobiology, engaging immune cells through mechanical signals to restore and enhance their activity. By mimicking the beneficial cellular forces experienced during physical activity, LIV aims to combat immune exhaustion and support existing therapeutic strategies. The technology targets cellular mechanosensitive pathways, offering a drug-free modality to improve immune cell activation, proliferation, and resilience, even in compromised immune states.
Target Audience
The primary target audience includes biotechnology and pharmaceutical companies seeking novel therapeutic modalities, as well as researchers in immunology and aging focused on immune system enhancement.
Features
- Low-Intensity Vibration (LIV) technology for non-invasive immune modulation.
- Mechanobiology-based approach targeting cellular cytoskeleton, nucleus, and signaling networks.
- Enhances immune cell activation, proliferation, and resilience through mechanical stimulation.
- Addresses immune exhaustion and age-related immune decline.
- Potential adjuvant therapy to improve efficacy of cancer immunotherapies, such as checkpoint inhibitors and cellular therapies.
- Reactivates aged immune cells by engaging CD-28 costimulatory signaling pathways.
- Drug-free therapeutic modality.